Vital Health Podcast
By Vital Health Podcast
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Vital Health Podcast
Category: Science
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 7
Reviews: 0
Episodes: 100
Description
Duane Schulthess is the CEO of Vital Transformation, host and producer of Vital Health Podcast. Vital Transformation understands the implications of new medical procedures, technologies and regulations. We measure their impact upon treatment pathways and the biopharma innovation ecosystem in collaboration with health care professionals, researchers, and regulators. Through our web platform and client network, we are able to communicate our findings with international decision makers and stakeholders.
| Episode | Date |
|---|---|
|
Steve Usdin: Tariffs, Price Controls, & Inflation Reduction Act (IRA)
|
Apr 23, 2025 |
|
Expanding Oncology Treatments: PRIME-ROSE and the Future of Drug Repurposing
|
Feb 21, 2025 |
|
Breaking Barriers: The Prime Rose Project and Off-Label Drug Innovations
|
Dec 18, 2024 |
|
Impact of the Inflation Reduction Act on Venture Capital in Life Sciences
|
Dec 11, 2024 |
|
Investing in Health: Pathways to a Well-being Economy and Smarter Healthcare Budgets
|
Nov 20, 2024 |
|
Addressing Europe's Health Challenges: Innovation, Prevention, and Policy
|
Nov 06, 2024 |
|
The Future of Biotech: Steve Potts on Innovation, Policy, and the Impact of the IRA
|
Oct 07, 2024 |
|
Revolutionizing Healthcare with Real-World Data
|
Sep 25, 2024 |
|
Exploring the Intersection of Intellectual Property and Biotech Innovation
|
Sep 18, 2024 |
|
Unlocking the Power of Genomic Data: NashBIO's Role in Healthcare Innovation
|
Sep 13, 2024 |
|
MEP Pernille Weiss – Rapporteur of the EU GPL
|
Sep 04, 2024 |
|
Transforming Health Communications: Insights from Virginia Amann
|
Aug 22, 2024 |
|
Joe Panetta – Policy Impacts on California Biopharma
|
Aug 01, 2024 |
|
Niklas Blomberg, Executive Director, EU Innovative Health Initiative
|
Jul 03, 2024 |
|
Congressman Michael Burgess – IRA and March-in Rights
|
Jun 19, 2024 |
|
Kim Hawkins - Project Co-Lead of IMI’s Trials@Home
|
May 22, 2024 |
|
Douglas Holtz-Eakin, “Indications are going to be deeply affected by the IRA”
|
May 01, 2024 |
|
John LaMattina – Drug Price Controls and IP Attacks Get Real
|
Mar 27, 2024 |
|
Kate Hudson & Joseph P. Allen – The Fact Free Attacks on IP
|
Mar 21, 2024 |
|
VT’s Grumpy Old Men – The Administration’s Threats to use March-In Rights
|
Mar 14, 2024 |
|
PRIME-ROSE: The EU’s DRUP Trial Champion
|
Feb 07, 2024 |
|
Peter Kolchinsky - "IRA's 9 Years Is Too Short"
|
Jan 17, 2024 |
|
Christian Schneider, CMO Biopharma Excellence
|
Nov 08, 2023 |
|
Bettina Ryll at the 2023 ESMO Conference
|
Nov 01, 2023 |
|
Dan Leonard, Executive Director, We Work For Health
|
Oct 11, 2023 |
|
Cancer Drug Developer Dr. Steve Potts' Congressional Testimony on the IRA
|
Sep 27, 2023 |
|
Amy Miller and the PhRMA Foundation Push the R&D Envelope
|
Sep 20, 2023 |
|
VT’s Grumpy Old Men on Price Controls and IP Attacks
|
Sep 13, 2023 |
|
Taking the Helm Mid Drug Pricing Maelstrom
|
Sep 06, 2023 |
|
Best-of Edition: Looking back on the COVID-19 outbreak part 2
|
Aug 24, 2023 |
|
Best-of Edition: Looking back on the COVID-19 outbreak
|
Aug 10, 2023 |
|
CMS' Restrictions on Alzheimer's Drugs
|
Aug 01, 2023 |
|
Biocom California Grapples with Regulatory Assaults on all Fronts
|
Jul 20, 2023 |
|
Amitabh Chandra - IRA’s potential impact on the US biopharma ecosystem
|
Jul 12, 2023 |
|
NJ’s Biopharma Sector in a Price Controlled World
|
Jul 06, 2023 |
|
IRA’s Impact on Orphan Therapies – David Meeker
|
Jun 29, 2023 |
|
Nick Shipley - IRA’s Impact on the Biopharma Ecosystem
|
Jun 23, 2023 |
|
Nikolai Brun - Improving Europe's Biopharma Legislation
|
May 31, 2023 |
|
EU Cost Effectiveness Models Threaten Vulnerable U.S. Patients
|
May 17, 2023 |
|
Andrew Roddam, CEO of Our Future Health
|
May 11, 2023 |
|
Attacks on Bayh-Dole Put University Research at Risk
|
May 04, 2023 |
|
California Life Sciences’ Response to the Inflation Reduction Act
|
Mar 16, 2023 |
|
"Bayh–Dole Cannot be Used for Controlling Prices"
|
Mar 02, 2023 |
|
Price Controls put US Biopharma at Risk
|
Feb 16, 2023 |
|
Patrick Kilbride - The Dangers of March-In Rights
|
Feb 02, 2023 |
|
John LaMattina, Defending Pharma & Profits
|
Jan 25, 2023 |
|
Small Molecules Get Short Shrift, Jeff Jonker and the IRA
|
Dec 22, 2022 |
|
The Accelerated Approval Pathway is Vital for Rare Diseases
|
Dec 08, 2022 |
|
IRA's Impact on Biopharma Innovation with Amitabh Chandra
|
Dec 02, 2022 |
|
NovaQuest’s Devin Rosenthal on BioPharma Investing in a Post IRA World
|
Nov 11, 2022 |
|
Hans Sauer is Sour on the WTO’s Waivers of mRNA IP
|
Oct 28, 2022 |
|
NIH’s Impact on FDA Approvals is Statistically Zero, with Vital Transformation's Grumpy Old Men
|
Sep 30, 2022 |
|
Paul Neureiter on European Innovation, US Legislation, and China’s Biopharmaceutical Growth
|
Sep 15, 2022 |
|
CEOi’s John Dwyer on accelerated approvals, CMS, and Alzheimer’s Disease
|
Sep 08, 2022 |
|
SSR Health’s Richard Evans on Medicare Price Controls
|
Aug 10, 2022 |
|
Michele Oshman – Driving Innovation for the US’ Biotech State Associations
|
Aug 04, 2022 |
|
John M. O'Brien’s Hot Takes on March-in, Co-Pays, PBMs, CMS, and Patient Access
|
Jul 16, 2022 |
|
Rutgers’ Gary Branning Untangles a PBM Web of Complexity
|
Jul 08, 2022 |
|
Joe Panetta Steers Biocom California’s Members Through Increasingly Stormy Seas
|
Jul 01, 2022 |
|
Accelerated Approval Study Release - A Vital Pathway for Patients
|
Jun 22, 2022 |
|
Danny Seiden leads Arizona’s push against march-in rights
|
Jun 15, 2022 |
|
Flagship Pioneering’s Tom Dilenge On Accelerated Approvals
|
Apr 21, 2022 |
|
George Vradenburg, USAgainstAlzheimer's, and CMS' NCD
|
Apr 08, 2022 |
|
Sue Peschin - “CMS is in an untenable position” on Alzheimer’s disease
|
Mar 10, 2022 |
|
VT analyzed CMS' Alzheimer's disease draft guidance - it's REALLY bad
|
Feb 25, 2022 |
|
All Things Plasma Matter, Amy Efantis - CEO, Plasma Protein Therapeutics Association
|
Feb 14, 2022 |
|
Joan Koerber-Walker and AZBio, Will Drug Pricing Kill a Rising Phoenix?
|
Feb 10, 2022 |
|
John Murphy, is Build Back Better Bad for Biotech?
|
Dec 16, 2021 |
|
Miriam Sturkenboom & VAC4EU: Timing is everything
|
Oct 22, 2021 |
|
NCATS’ Chris Austin - R&D from NIH, to Industry, through Approval
|
Jul 20, 2021 |
|
About the NIH, Industry, and the R&D Ecosystem, with Richard Moscicki, PhRMA
|
Jul 08, 2021 |
|
Jack Scannell on Big Pharma’s Big Drug Discovery Problem
|
Jun 17, 2021 |
|
Is U.S. reference pricing a fatal shot for biotech?
|
May 05, 2021 |
|
KU Leuven Launches Health Innovation Fellowship
|
Mar 11, 2021 |
|
Ivermectin, Dr Pierre Kory’s magic bullet to fight COVID-19
|
Mar 02, 2021 |
|
Ivor Cummins, “The Fat Emperor” Takes on COVID-19 Lockdowns
|
Feb 05, 2021 |
|
PharmaCCX, a tech savvy solution for pricing EU cancer drugs
|
Jan 28, 2021 |
|
BIO’s New CEO Michelle McMurry-Heath, Taking Charge Amidst Chaos
|
Dec 11, 2020 |
|
Heidi Larson – Dispelling Vaccine Myths in the COVID-19 Era
|
Nov 19, 2020 |
|
Hack Healthcare’s Leo Exter and Awell Health’s Thomas Vande Casteele
|
Nov 10, 2020 |
|
Matt Wiener - EHDEN’s SME Marketplace and Harnessing Informatics
|
Oct 20, 2020 |
|
Kees van Bochove, A Hyve in EHDEN
|
Oct 12, 2020 |
|
NICE’s Jacoline Bouvy – Using EHDEN to Determine Value for Patients
|
Oct 05, 2020 |
|
Martin Kulldorff: "Herd immunity is a scientific fact"
|
Jun 19, 2020 |
|
OECD´s Francesca Colombo, At the Centre of the Covid-19 Storm
|
Jun 10, 2020 |
|
Yannis Natsis, Pricing and Advocacy under Covid-19
|
Jun 03, 2020 |
|
Wilfred Reilly: "There is no empirical evidence for these lockdowns."
|
May 22, 2020 |
|
Robert Madelin - Innovation and Leadership During a Pandemic
|
May 15, 2020 |
|
Dimitrios Athanasiou, a Duchenne Patient Advocate in the COVID-19 Era
|
May 12, 2020 |
|
Adrian van den Hoven, Providing Europe’s COVID-19 Medicine Arsenal
|
Apr 17, 2020 |
|
BIO CEO Jim Greenwood, An Innovation Led Assault on COVID19
|
Apr 08, 2020 |
|
Rick Grobbee - Trials@Home & Tribulations with COVID19
|
Mar 24, 2020 |
|
Better Science, Better Health: Sarah Garner, Managing Europe’s Innovation for the WHO
|
Jan 10, 2020 |
|
Biocom’s Joseph Panetta Discusses the Impact of IPI on the California Biotech Ecosystem
|
Dec 20, 2019 |
|
CLSA Challenges the U.S. Congress’ H.R. 3 in Support of California Biotech, Patients, and Innovation
|
Dec 02, 2019 |
|
Who Killed Healthcare? Dr Regina Herzlinger Knows Who’s Guilty
|
Nov 26, 2019 |
|
John LaMattina, former President Pfizer Global Research, on Medicare International Reference Pricing
|
Oct 30, 2019 |
|
Eduardo Bravo on Medicare Pricing Reform, Orphan Designations, and the EU Biotech Sector
|
Oct 22, 2019 |
|
Richard Barker, Famed U.K. Thought-Leader Discusses Precision Health, Pricing, and Brexit
|
Sep 30, 2019 |
|
The Alliance for Aging Research’s Sue Peschin Talks About Medicare Reform
|
Sep 11, 2019 |